AI assistant
Sending…
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2017
Oct 10, 2017
30849_dirs_2017-10-10_a66e5750-0556-44d6-ba2c-a78e99d51240.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2017-10-10
Reporting Person: Meeker David P (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-10-10 | Common Stock | C | 54525 | — | Acquired | 76335 | Direct |
| 2017-10-10 | Common Stock | P | 25000 | $17.00 | Acquired | 101335 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-10-10 | Series A Convertible Preferred Stock | $ | C | 54525 | Disposed | Common Stock (54525) | Direct |
Footnotes
F1: In connection with the closing of the Issuer's initial public offering, each share of the Issuer's series A convertible preferred stock (the "Series A Preferred") converted into the Issuer's common stock on a 9.17-for-one basis without payment or consideration. The Series A Preferred had no expiration date.
F2: Reflects the number of shares of Series A Preferred held by the Reporting Person on an as-converted to common stock basis.
More from RHYTHM PHARMACEUTICALS, INC.
Proxy Solicitation & Information Statement
2026
May 29
Regulatory Filings
2026
May 5
Regulatory Filings
2026
May 5
Proxy Solicitation & Information Statement
2026
Apr 29
Regulatory Filings
2026
Apr 3
Major Shareholding Notification
2026
Mar 27
Regulatory Filings
2026
Mar 20
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Mar 3